U.S. Markets closed

MiMedx Group, Inc. (MDXG)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
13.16-0.51 (-3.73%)
At close: 4:00PM EDT

13.16 0.00 (0.00%)
After hours: 4:55PM EDT

People also watch
OSIRHALONEOSUPNTGTX
  • A
    Angela
    Angela
    My husband has osteoarthritis. 3 years ago he was injected with some kind of derivative chicken gel . Each 3 time doses was $1700. Product did not work and after 3 months of treatment results were Zero..we demanded the refund of the money.Actually market products are not working for this growing problem even in the new generation school children, problem caused by GMO foods. So today's news on MDXG are really good. Get on board before too late
  • D
    David
    David
    Mdxg in their transcript last week - fully expects to take over the $10 billion osteoarthritis market.
  • A
    Angela
    Angela
    Still time to buy MDXG. And still time to check AH on Friday sept 15. Huge volume on buying side.over 1 million shares. Something good is cooking for MXDG. Same behavior on KITE days before been bought at 180...overnight jump $40.00
  • D
    David
    David
    If your company has the cure for arthritis, your company should be valued at minimum $50 billion dollars.
  • A
    Angela
    Angela
    AH...today's buyers coming more than usual.....hummm. Smiling may be something good is cooking -:)
  • P
    PS
    PS
    Expecting Q3 revenues between $82M - 83M... should get the stock to $17 -$18
  • D
    David
    David
    Do yourself a favor. Go read the Morgan Stanley transcript from Tuesday. Wink wink - alter OA disease state and we will own that $10 billion market. Now explain why you would not own part of this company.
  • J
    John V
    John V
    it maybe 3 months but well see 18 before 12... business performance is outstanding, strong numbers, growth etc the employee lawsuit on channel stuffing is a joke and they've already proved this was false.

    shorts are pulling this down, but reminder that as this slips lower it just makes it sooo much more attractive to an acquirer of MDXG for $25+ share and the 22M current shorts will get crushed!!!!!!
  • D
    D11
    D11
    If you haven't figured it out yet, CezCandE is one of Get a Clue!'s alternate names...only uses this one to bash MDXG
  • A
    Angela
    Angela
    REVERSING to upside. Candle pattern plus other Indicators. Same as MZOR
  • L
    Louis
    Louis
    hey everybody let's start posting on race and pdli and Bash it
  • B
    Beef
    Beef
    MiMedx Recognized As Number 5 On Fortune Magazine's List Of The 100 Fastest Growing Public Companies
  • P
    PS
    PS
    Positive OA results will be transformational for the company... The primary end point of pain reduction at 3 months should be easily met... Will propel to stock to 20+
  • D
    David
    David
    Welcome back haters. Can't wait for you to disappear again in 2 weeks.
  • A
    Andy
    Andy
    Hmmmm, the Needham target boost price on September 9 is looking a little suspicious. Is it possible they boosted the price target in order to drum up some positive activity in the stock while at the same time their clients were selling (or they were selling). Say it isn't so !!!
  • m
    minnesotafarmcountry
    minnesotafarmcountry
    Why don't the greedy shorts just cover ... the opening flush to run stops is getting old! Creating FUD ...
  • N
    Nikolce
    Nikolce
    MDXG is highly overvalued 74 PE. It went from $8.20 to $17.5 in 5 months. The stock ran too fast to high. Nothing is wrong with the company. Reversal and profit taking are normal with this kind of stock movement.
  • P
    PS
    PS
    Quite disturbing to see that a great company like MiMedx with unique technology, market leadership and immense potential grossly undervalued... The market cap of this company today should be around $3 Billion... What's wrong?
  • L
    Louis
    Louis
    MiMedx Recognized as Number 5 on Fortune Magazine's List of the 100 Fastest Growing Public Companies

    PR Newswire PR NewswireSeptember 12, 2017Comment
    MARIETTA, Ga., Sept. 12, 2017 /PRNewswire/ -- MiMedx Group, Inc. (MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today that the Company has been recognized by Fortune Magazine as the fifth ranked company in Fortune's 2017 list of the top 100 fastest growing public companies.

    The methodology utilized by Fortune Magazine for its ranking of the top 100 fastest growing public companies includes the company must be listed on a major U. S. stock exchange; have a minimum market capitalization of $250 million and a stock price of at least $5 on June 30, 2017; and have been trading continuously since June 30, 2014. These companies must have revenue and net income for the four quarters ended on or before April 30, 2017 of at least $50 million and $10 million, respectively; and have posted an annualized growth in revenue and earnings per share (EPS) of at least 15% annually over the three years ended on or before April 30, 2017.

    Companies that meet these criteria are ranked by revenue growth rate, EPS growth rate, and three-year annualized total return for the period ended June 30, 2017. Fortune determines the overall rank based on the sum of the three ranks. Once the 100 companies are identified, they are then re-ranked within the 100, using these three equally weighted variables.
  • m
    minnesotafarmcountry
    minnesotafarmcountry
    Man, the shorts have their boot on MDXG's throat!! Relentless and Pete keeps firing at them!